Lung Cancer in Renal Transplant Recipients

Mirela Jozićic1, Alen Imsirovic1, Lea Katalinic2, Branimir Krtalic3 and Nikolina Basic Jukić1,2,3

1University of Josip Juraj Strossmayer in Osijek, Medical Faculty, Osijek, 2Department of nephrology, arterial hypertension, dialysis and transplantation, University hospital centre Zagreb, 3School of medicine, University of Zagreb, Zagreb, Croatia

Abstract

Introduction. Although the incidence of malignancy has increased after solid organ transplantation, data on lung cancer in this group of patients is scarce. The aim of this study was to determine clinical characteristics and outcome of patients who developed lung cancer after renal transplantation.

Methods. Among a cohort of 1658 patients who received a transplant at our institution and were followed-up between 1973 and 2014, five patients developed lung cancer. We analyzed risk factors, transplantation characteristics, treatment options and survival.

Results. Lung cancer was diagnosed in 5 patients (0.3%). Time to diagnosis after the transplant procedure ranged from 26 to 156 months (mean 115 months). All of them had a smoking history. Tumors were classified as IIB (20%), IIIA (40%), and IV (40%). Histological types included adenocarcinoma (80%) and there was one case of sarcomatoid carcinoma (20%). One patient had concomitant thyroid papillary carcinoma. Radiotherapy was applied in 2 patients, 2 underwent chemotherapy (erlotinib and combination of carboplatinum and etoposide in one patient each), and 2 died within one month after the diagnosis from disseminated malignant disease. Patients with stage IIIA survived 14 and 24 months after the diagnosis. The patient with sarcomatoid cancer underwent thoracotomy with a complete resection, lost his graft function and died 7 months after the diagnosis.

Conclusion. Lung cancer is relatively rare malignancy in renal transplant recipients, but associated with high mortality. Smoking is a significant risk factor, thus smoking cessation should be promoted among renal transplant recipients, as well as regular screening for lung cancer.

Keywords: lung cancer, kidney transplantation, smoking
Among a cohort of 1658 patients who received a transplant at our institution and were followed-up between 1973 and 2014, 5 patients developed lung cancer. Time to diagnosis after the transplant procedure ranged from 26 to 156 months (mean 115 months). All patients who developed lung malignancy had a long-term (more than 20 years) smoking history. Immunosuppressive protocol included cyclosporine in 3 and tacrolimus in 2 patients, with mycophenolate mofetil and steroids. Three patients received basiliximab induction, two were transplanted without induction. Tumors were classified as IIB (one patient), IIIA (two patients), and IV (two patients). Histological types included adenocarcinoma (n=4; 80%) and there was one case of sarcomatoid carcinoma (n=1; 20%). One patient had concomitant thyroid papillary carcinoma.

Treatment protocol varied depending on the severity of disease. Two patients were treated with radiotherapy, and two with chemotherapy (erlotinib in one patient, and a combination of carboplatinum and etoposide in the other). The patient with sarcomatoid carcinoma was treated with thoracotomy with complete resection. The outcome was poor. Two patients died one month after the diagnosis. Patients with stage IIIA survived 14 and 24 months after the diagnosis. The patient with sarcomatoid cancer had lost his graft function and died 7 months after the diagnosis. All patients refused to stop immunosuppressive treatment and undergo pneumectomy. They were switched from cyclosporine or tacrolimus to mTOR-based immunosuppressive protocol.

**Lung cancer in national registries or studies**

Few studies have focused on lung cancer in renal transplant recipients. In Table 1 we present the incidence in transplant population in Croatia and other countries.

<table>
<thead>
<tr>
<th>Country</th>
<th>Our cohort</th>
<th>Turkey</th>
<th>China</th>
<th>England</th>
<th>Australia</th>
<th>New Zealand</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of recipients</td>
<td>1 658</td>
<td>4 000</td>
<td>3 462</td>
<td>25 104</td>
<td>3 129 083</td>
<td>605 538</td>
</tr>
<tr>
<td>Time interval (years)</td>
<td>41</td>
<td>4,5</td>
<td>40</td>
<td>27</td>
<td>11</td>
<td>11</td>
</tr>
<tr>
<td>Incidence (%)</td>
<td>0.3</td>
<td>6</td>
<td>0.8</td>
<td>1.4</td>
<td>1.2</td>
<td>1.3</td>
</tr>
</tbody>
</table>

**Discussion**

The incidence of lung cancer has been particularly increased in recipients of heart and lung transplants, which may be related to the strong influence of cigarette smoking on the development of heart and lung diseases [11]. However, lung cancer may complicate posttransplant course after renal transplantation as well.

This study demonstrates that in our cohort of renal transplant recipients lung cancer is relatively rare malignancy, but has high mortality rate. Patients were diagnosed at advanced stage.

In the general population, non-small cell lung cancer accounts for about 85% of lung cancers and includes: adenocarcinoma which is the most common form of lung cancer among both genders; squamous cell carcinoma which accounts for approximately 25%, and large cell carcinoma which accounts for 10% of non-small cell lung malignancies. The remaining 15% of lung cancers are small lung cancer. Four patients from our cohort had non-small cell cancers and one was diagnosed with sarcomatoid carcinoma. Significant differences may be noted among different countries. Based on data from the Croatian registry of malignant diseases in the general population, there were 2031 new cases of lung cancer in males and 722 in females in 2013. In the general public, lung cancer is the most common cancer in males, and third in females after breast and colorectal cancer, with the crude rate for males 98.3; for females 32.6, while total crude rate is 64.2 [12]. Thus, lung cancer that is frequent in the Croatian general population is rare in renal transplant population in our cohort of patients. Turkey has a very high prevalence of lung cancer among renal transplant recipients, while Croatia and China have low prevalence [7,8].

**Conclusion**

All patients who developed lung malignancy continued with smoking after transplantation despite the warnings from nephrologists. Since smoking represents the leading risk factor for development of lung malignancy we should encourage patients to quit smoking, and promote a screening program in this population for early discovery of lung cancer, with annual chest X-rays.

**Conflict of interest statement.** None declared.

**References**